Iovance Biotherapeutics was the first drug developer to win FDA approval of an immune cell/T-cell therapy. The underlying ...

Bristol Myers BMY recently announced that it will acquire privately held biotechnology company Orbital Therapeutics for $1.5 ...

Several pharmaceutical companies showcased data on their BTK inhibitors at the ASCO 2023 conference, including Ono ...

AstraZeneca has agreed to lower prescription drug costs for Medicaid under a deal with the Trump administration.

Prof David Kerr discusses a recent study investigating tumor mutational burden as a potential contributing factor to ...

Providence Cancer Institute’s executive medical director, Bryan Bell, M.D., D.D.S, FACS, FRCS(Ed), recently discussed recent ...

AstraZeneca advances its ambition to redefine cancer care with new data across its diverse, industry-leading portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress, ...

Confirmation of 30mg efti as optimal biological dose relevant for Immutep’s oncology pipeline and potential future Biological License ...

Primary overall survival analysis from the Phase 3 monarchE study of Verzenio (abemaciclib) in HR+HER2-, node-positive, high-risk early breast cancer to ...

Medical artificial intelligence (AI) company Lunit announced on October 13 that it will present three studies on predicting immunotherapy response ...